Abbott cuts prices to VHA under renegotiated sole-source contract, adds Carpuject syringe to agreement.
This article was originally published in The Gray Sheet
Executive Summary
ABBOTT/VHA SUPPLY DEAL RENEGOTIATED IN RESPONSE TO PRICING PRESSURE for intravenous supplies and other products covered under the contract. Abbott's existing sole-source deal with VHA was set to expire in 1999, but VHA renegotiated the agreement in light of lower prices in markets covered by the deal. The supply pact includes I.V. supplies, parenteral nutritionals and compounding systems, electronic drug delivery systems, critical care products, and injectable drugs and delivery systems.